STRATA CRITICAL MEDICAL, INC. Net Income (Loss) Available to Common Stockholders, Diluted
STRATA CRITICAL MEDICAL, INC. (SRTA) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$1.95 million for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2024-11-12
- STRATA CRITICAL MEDICAL, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2024-09-30 was -$1.95M, a 826.39% decline year-over-year.
- STRATA CRITICAL MEDICAL, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2023-09-30 was $269.00K.
- STRATA CRITICAL MEDICAL, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2023-06-30 was -$12.23M, a 249.55% decline year-over-year.
- STRATA CRITICAL MEDICAL, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2022-12-31 was -$15.41M, a 2136.33% decline year-over-year.
- STRATA CRITICAL MEDICAL, INC. net income (loss) available to common stockholders, diluted for fiscal 2022 was -$27.26M.
- STRATA CRITICAL MEDICAL, INC. net income (loss) available to common stockholders, diluted for fiscal 2020 was -$21.01M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 1 month | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 4 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 7 month | Net Income (Loss) Available to Common Stockholders, Diluted 7 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | -$1.95M 10-Q · filed 2024-11-12 | -$17.51M 10-Q · filed 2024-11-12 | ||||||||
| 2023-09-30 | $269.00K 10-Q · filed 2024-11-12 | -$11.96M derived: sum of 2 quarters · filed 2024-11-12 | -$22.14M 10-Q · filed 2024-11-12 | |||||||
| 2023-06-30 | -$12.23M 10-Q · filed 2023-08-09 | -$22.42M 10-Q · filed 2023-08-09 | ||||||||
| 2022-12-31 | -$15.41M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$24.66M derived: sum of 2 quarters · filed 2023-11-08 | -$16.48M derived: sum of 3 quarters · filed 2023-11-08 | -$27.26M 10-K · filed 2023-03-16 | ||||||
| 2022-09-30 | -$9.24M 10-Q · filed 2023-11-08 | -$1.07M derived: sum of 2 quarters · filed 2023-11-08 | -$11.85M 10-Q · filed 2023-11-08 | |||||||
| 2022-06-30 | $8.18M 10-Q · filed 2023-08-09 | -$2.60M 10-Q · filed 2023-08-09 | ||||||||
| 2021-12-31 | $757.00K 10-K · filed 2023-03-16 | -$10.79M derived: sum of 2 quarters · filed 2023-03-16 | -$35.07M derived: sum of 3 quarters · filed 2023-03-16 | -$36.15M derived: sum of 4 quarters · filed 2023-03-16 | ||||||
| 2021-09-30 | -$11.54M derived: 10-K 9 month − 10-Q 6 month · filed 2023-03-16 | -$35.83M derived: sum of 2 quarters · filed 2023-03-16 | -$40.05M 10-K · filed 2023-03-16 | -$39.27M derived: sum of 4 quarters · filed 2023-03-16 | ||||||
| 2021-06-30 | -$24.29M 10-Q · filed 2022-08-09 | -$28.51M 10-Q · filed 2022-08-09 | -$27.73M derived: sum of 3 quarters · filed 2023-01-10 | -$27.84M derived: sum of 4 quarters · filed 2023-01-10 | ||||||
| 2021-03-31 | -$1.08M 10-Q · filed 2021-05-24 | -$3.44M derived: sum of 2 quarters · filed 2023-01-10 | -$3.55M derived: sum of 3 quarters · filed 2023-01-10 | -$3.61M derived: sum of 4 quarters · filed 2023-01-10 | ||||||
| 2020-12-31 | -$2.36M 8-K · filed 2023-01-10 | -$2.47M derived: sum of 2 quarters · filed 2023-01-10 | -$2.53M derived: sum of 3 quarters · filed 2023-01-10 | -$21.01M 10-K/A · filed 2021-05-07 | -$444.56K 10-K · filed 2021-03-10 | |||||
| 2020-09-30 | -$110.17K 10-Q · filed 2020-11-10 | -$172.82K derived: sum of 2 quarters · filed 2020-11-10 | -$234.95K 10-Q · filed 2020-11-10 | |||||||
| 2020-06-30 | -$62.65K 10-Q · filed 2020-08-13 | -$125.22K 10-Q · filed 2020-08-13 | ||||||||
| 2020-03-31 | $5.06M 10-Q · filed 2021-05-24 | -$62.70K 10-Q · filed 2020-05-13 | ||||||||
| 2019-12-31 | $1.50M 10-K/A · filed 2021-05-07 | -$101.81K 10-K · filed 2020-03-20 | ||||||||
| 2019-09-30 | -$36.27K 10-Q · filed 2020-11-10 | -$37.27K 10-Q · filed 2020-11-10 | ||||||||
| 2019-06-30 | -$1.00K 10-Q · filed 2020-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DocGo Inc. (DCGO) | United States | $0.034B | -0.25 |
| VSEE HEALTH, INC. (VSEE) | United States | $0.003B | |
| Agape ATP Corp (ATPC) | $0.002B | ||
| InnovAge Holding Corp. (INNV) | United States | $1.206B | -635.60 |
| Omada Health, Inc. (OMDA) | United States | $1.207B | 309.08 |
| U S PHYSICAL THERAPY INC /NV (USPH) | United States | $1.251B | 32.48 |
| Pennant Group, Inc. (PNTG) | United States | $1.386B | 39.84 |
| Privia Health Group, Inc. (PRVA) | United States | $2.477B | 115.52 |
| GeneDx Holdings Corp. (WGS) | United States | $2.638B | -19.23 |
| LifeStance Health Group, Inc. (LFST) | United States | $4.510B | 80.86 |